{
    "organizations": [],
    "uuid": "daff84e87edcf8eb29de6461582d7324c0d181be",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-transgene-announces-dosing-of-firs/brief-transgene-announces-dosing-of-first-patient-in-phase-2-trial-of-tg4010-evaluation-idUSFWN1PB18S",
    "ord_in_thread": 0,
    "title": "BRIEF-Transgene Announces ‍Dosing Of First Patient In Phase 2 Trial Of TG4010 Evaluation ​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 16 (Reuters) - Transgene Sa:\n* ‍FIRST PATIENT DOSED IN A PHASE 2 TRIAL WITH TRANSGENE‘S TG4010 + NIVOLUMAB + CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF LUNG CANCER (NSCLC)​\n* ‍FIRST RESULTS EXPECTED IN H2 2018​ * ‍THIS MULTI-CENTER SINGLE-ARM TRIAL WILL ENROLL UP TO 39 PATIENTS BOTH IN USA AND EUROPE​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-17T01:01:00.000+02:00",
    "crawled": "2018-01-17T20:09:24.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "transgene",
        "sa",
        "patient",
        "dosed",
        "phase",
        "trial",
        "transgene",
        "tg4010",
        "nivolumab",
        "chemotherapy",
        "treatment",
        "lung",
        "cancer",
        "nsclc",
        "result",
        "expected",
        "h2",
        "trial",
        "enroll",
        "patient",
        "usa",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}